Medscape1mon
Cardiac Amyloidosis: An Approach to Diagnosis and Management
[1] Amyloidosis is the most frequent cause of restrictive cardiomyopathy in the Western world. Unfortunately, this disease is generally misdiagnosed and its natural history and outcomes differ ...
Yahoo Finance3d
Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program
This clearance makes EchoGo ® Amyloidosis the first commercially available software-only medical device to facilitate detection of Cardiac Amyloidosis using echocardiography. Requiring a single ...
emjreviews.com1d
Kidney Decline: A Key Predictor of Transthyretin Amyloid Cardiomyopathy Mortality
Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.
Healthline10d
ATTR Amyloidosis Symptoms, Diagnosis, and Treatments
ATTR amyloidosis results from the buildup of ... Both hATTR and ATTRwt increase your risk of cardiomyopathy and heart failure. However, neuropathy (a problem with your nervous system) is a common ...
EurekAlert!6d
Kidney outcomes in transthyretin amyloid cardiomyopathy
In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of ...
Business Wire1mon
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
“We are proud that with this first regulatory submission, we are a significant step closer to bringing vutrisiran to patients with ATTR amyloidosis with cardiomyopathy, which is a steadily ...
Nasdaq1mon
Alnylam Submits SNDA For Vutrisiran To Treat ATTR Amyloidosis With Cardiomyopathy
an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA, which is currently approved by ...
Women’s Silent Heart Threat: ATTR-CM Unveiled
Heart failure can be a scary diagnosis. But what if there’s something else going on that’s even harder to spot? Meet ...
Business Wire1mon
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved ...